Onconetix, Inc. financial data

Symbol
ONCO on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 E. Fifth Street, Suite 1900, Cincinnati, Ohio
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Blue Water Biotech, Inc. (to 12/18/2023), Blue Water Vaccines Inc. (to 4/20/2023)
Latest financial report
10-Q - Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 48.4 % -93.3%
Quick Ratio 4.9 %
Return On Equity -112 % -57.5%
Return On Assets -68.7 % -14.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.3M shares
Common Stock, Shares, Outstanding 22.3M shares +40.6%
Entity Public Float 13M USD +32.7%
Common Stock, Value, Issued 228 USD +39%
Weighted Average Number of Shares Outstanding, Basic 22.1M shares +39.2%
Weighted Average Number of Shares Outstanding, Diluted 22.1M shares +39.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 700K USD
Cost of Revenue 511K USD
Research and Development Expense 916K USD -80.7%
General and Administrative Expense 8.8M USD +41.8%
Operating Income (Loss) -44.3M USD -210%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -11.2M USD -295%
Net Income (Loss) Attributable to Parent -11.1M USD -291%
Earnings Per Share, Basic -2.51 USD/shares -167%
Earnings Per Share, Diluted -2.51 USD/shares -167%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.8M USD +1235%
Accounts Receivable, after Allowance for Credit Loss, Current 253K USD
Inventory, Net 396K USD
Assets, Current 6.29M USD -72%
Property, Plant and Equipment, Net 56.8K USD +299%
Operating Lease, Right-of-Use Asset 109K USD
Intangible Assets, Net (Excluding Goodwill) 21.5M USD
Goodwill 46.7M USD
Assets 75M USD +233%
Accounts Payable, Current 4.25M USD +183%
Accrued Liabilities, Current 1.94M USD +49.7%
Liabilities, Current 21.4M USD +663%
Deferred Income Tax Liabilities, Net 2.74M USD
Operating Lease, Liability, Noncurrent 46.9K USD
Liabilities 25.3M USD +801%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.46M USD
Retained Earnings (Accumulated Deficit) -67.9M USD -206%
Stockholders' Equity Attributable to Parent -21.5M USD -209%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -14.5M USD -174%
Liabilities and Equity 75M USD +233%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.23M USD -18.6%
Net Cash Provided by (Used in) Financing Activities 5.21M USD
Net Cash Provided by (Used in) Investing Activities -4.58K USD +87.4%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 22.8M shares +39.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -90.5K USD +98%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.46M USD -79%
Deferred Tax Assets, Valuation Allowance 15.7M USD +248%
Deferred Tax Assets, Gross 17M USD +277%
Depreciation 1.7K USD +30.6%
Payments to Acquire Property, Plant, and Equipment 4.58K USD +152%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16M USD -460%
Operating Lease, Liability, Current 62.5K USD
Deferred Income Tax Expense (Benefit) -122K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.2M USD +242%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 17K USD 0%
Additional Paid in Capital 49.5M USD +16.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 207K USD +12073%
Deferred Tax Assets, Net of Valuation Allowance 1.3M USD +43275%
Share-based Payment Arrangement, Expense 52.7K USD -71.6%
Interest Expense 269K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%